We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Research Progress of Immune Checkpoint Inhibitor-associated Myocarditis.
- Authors
Yunwei LIU; Yanxin CHEN; Zhimin ZENG; Anwen LIU
- Abstract
Immune checkpoint inhibitors (ICIs) is a negative regulatory factor antibody, which activates T cells to play an anti-tumor effect in immunotherapy, and can also cause immune-related adverse responses, thereby inducing a series of immune related adverse events (irAEs). Among these irAEs, although the incidence of ICIs-related myocarditis is very low, the fatality rate is significantly higher than other adverse reactions, close to 50%. Clinicians should be vigilant when applying ICIs, but the pathogenesis of ICIs-related myocarditis is still unclear. This article combines the recent research results of ICIs to summarize the mechanism and clinical manifestations of ICIs-related myocarditis, so as to improve clinicians' understanding of the adverse reactions.
- Subjects
CARDIOTOXICITY; IMMUNE checkpoint inhibitors; IMMUNOGLOBULINS; CARDIOMYOPATHIES; DRUG side effects; MEDICAL research; IMMUNOTHERAPY
- Publication
Chinese Journal of Lung Cancer, 2021, Vol 24, Issue 9, p668
- ISSN
1009-3419
- Publication type
Academic Journal
- DOI
10.3779/j.issn.1009-3419.2021.102.27